DescriptionCurator's Comment:: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Curator's Comment:: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19417616 |
169.5 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ATRACURIUM BESYLATE Approved UseAtracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date8.6918398E11 |
PubMed
Title | Date | PubMed |
---|---|---|
Leaking abdominal aortic aneurysm on anticoagulants-thromboelastography assisted management. | 2009 Jun |
|
A prospective randomized double blind study to evaluate the effect of infusion of amino Acid enriched solution on recovery from neuromuscular blockade. | 2009 Jun |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage. | 2010 Feb 6 |
|
Wound contraction and macro-deformation during negative pressure therapy of sternotomy wounds. | 2010 Sep 30 |
Patents
Sample Use Guides
An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2720863
Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).
Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Jun 25 21:04:52 UTC 2021
by
admin
on
Fri Jun 25 21:04:52 UTC 2021
|
Record UNII |
40AX66P76P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4734
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
SUB05603MIG
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
264-743-4
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
DB00732
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
1219
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | RxNorm | ||
|
1044800
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | USP-RS | ||
|
C28839
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
CHEMBL1360
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
64228-81-5
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
64228-81-5
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
M2129
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | Merck Index | ||
|
40AX66P76P
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY | |||
|
ATRACURIUM BESILATE
Created by
admin on Fri Jun 25 21:04:52 UTC 2021 , Edited by admin on Fri Jun 25 21:04:52 UTC 2021
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |